Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs Vistra Corp (VST) Price & Performance

Vistra CorpTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs Vistra Corp — how do they compare? Sanofi SA trades at $43.6 (market cap $104.30B), while Vistra Corp trades at $146.69 (market cap $48.64B). The key difference: Sanofi SA is far larger — about 2.1× Vistra Corp's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

SNYVST
Market Cap
$104.30B$48.64B
Sector
HealthTechnology
52-Week High
$52.34$217.92
52-Week Low
$41.33$134.71
Enterprise Value
$124.19B$70.58B
Dividend Yield
5.55%0.63%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.

The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.

Vistra Corp

Vistra (VST) trades at $146.68, up 2.67% today, with a bearish technical signal from moving averages but strong analyst support (90.9% buy ratings). Recent Q2 2026 earnings showed a beat on EPS ($2.87 actual vs. $1.32 expected) but a revenue miss, while the company reaffirmed full-year guidance amid growing data center power demand. The stock's valuation includes a P/E of 24.44 and a high ROE of 75.73%, though net cash flow was negative in 2025.

The outlook is positive due to robust EBITDA growth and strategic positioning in the AI power sector, with a consensus price target of $239.75 implying significant upside. Key risks include ERCOT market volatility, hedging losses, and high debt levels, requiring monitoring of execution on data center deals and cost controls.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY

About Vistra Corp

Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.

Read more on VST